Akeega access in India: the CDSCO Rule 36 named-patient pathway
How families in India legally obtain Akeega (niraparib + abiraterone acetate fixed-dose oral combination) for BRCA-mutated metastatic prostate cancer from US-source supply through CDSCO personal importation, with BRCA confirmation and PARP-class monitoring built into the case plan.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Akeega in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Akeega is a Janssen fixed-dose combination oral tablet containing niraparib (a poly(ADP-ribose) polymerase, or PARP, inhibitor) and abiraterone acetate (a CYP17 inhibitor that blocks androgen biosynthesis), the first dual-action tablet of its kind for prostate cancer. The US Food and Drug Administration approved Akeega on 11 August 2023 in combination with prednisone for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), with a December 2025 label extension to BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). BRCA testing through an FDA-approved companion diagnostic (such as FoundationOne CDx) is mandatory before initiation. Akeega is not registered with the CDSCO as of this review. Indian patients with confirmed BRCA-mutated metastatic prostate cancer reach Akeega through the Central Drugs Standard Control Organization (CDSCO) personal importation framework under Rule 36 of the Drugs and Cosmetics Rules 1945, with the Form 12A application and Form 12B permit issued by the office of the Drugs Controller General of India (DCGI). Reserve Meds coordinates supply through a US-licensed pharmaceutical wholesale partner, ambient-temperature pharmaceutical logistics, and the documentation kit your treating oncologist needs to file.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
Why patients in India need Akeega via the named-patient pathway
For the subset of patients who have completed BRCA testing and have a confirmed deleterious or suspected deleterious BRCA1 or BRCA2 mutation, the FDA-approved PARP-plus-androgen-axis combinations become clinically actionable.
Akeega is not on the CDSCO register. The separate components are available in India in different forms: abiraterone acetate and niraparib may each be available locally in some form, and your oncologist can confirm current local supply. Running the components separately on two prescriptions is medically feasible but operationally heavier on the patient and the family, particularly when the patient is managing prednisone, ongoing androgen deprivation therapy (such as a GnRH analogue), and the adherence schedule across distinct dispensing pipelines. The fixed-dose tablet is the preferred procurement route when patients and oncologists prefer adherence simplicity, and Rule 36 is the legal vehicle for the unregistered fixed-dose product.
Cash-pay, often through diaspora-funded structures, is the working financial posture for Akeega cases.
The CDSCO Rule 36 named-patient pathway for Akeega
The legal foundation for personal import of an unregistered medicine into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits the import of a small quantity of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient. Form 12A is the application for the permit. Form 12B is the permit itself, issued by the office of the DCGI at FDA Bhawan, Kotla Road, New Delhi, or by designated CDSCO Port Offices. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission (NMC) registration number and the quantity required for treatment. The quantity of any single drug imported is capped at one hundred average doses per application.
For Akeega specifically, the clinical-justification angle in a Form 12A application is the BRCA-confirmation requirement that is the gating clinical criterion in the FDA label. The strongest applications consistently include a treating oncologist's confirmed diagnosis of metastatic prostate cancer (with castration status documented to distinguish mCRPC from mCSPC, given the two separate FDA-approved indications); the BRCA mutation result from an FDA-recognized companion diagnostic or equivalent comprehensive genomic profiling panel, with the testing laboratory named (FoundationOne CDx is the FDA-approved companion diagnostic); the documented prior therapies tried and failed where the patient is on the mCRPC pathway; the proposed daily dose (200 mg niraparib plus 1,000 mg abiraterone acetate orally once daily on an empty stomach, with prednisone 10 mg once daily, and ongoing androgen deprivation therapy continued unless the patient has undergone bilateral orchiectomy); and the PARP-class monitoring plan covering complete blood count weekly for the first month then monthly during treatment, blood pressure, liver function tests, serum potassium, and long-term vigilance for myelodysplastic syndrome and acute myeloid leukemia.
For institutional Compassionate Use of drugs not approved for marketing in India at all, the parallel pathway is the Compassionate Use application route to the DCGI by a government hospital, a registered medical practitioner, a pharmaceutical company, or the patient. This route applies when the drug is approved by a recognised reference authority (FDA, EMA, MHRA, Health Canada, PMDA) for an unmet medical need. Akeega qualifies under FDA and EMA approval. CDSCO decides on the Form 12B permit after it reviews a complete Form 12A filing, and first-time or complex imports can take longer. We give you a written timeline estimate for your case before you commit. Indian families and hospitals plan for a two to four week window from oncologist decision to first dose, because the bulk of elapsed time runs through upstream documentation assembly (most notably BRCA confirmation if not already complete) and downstream international logistics rather than the regulator's stamp.
Where Akeega gets dispensed in India
Akeega is an oral solid-dose product. It is stable at controlled room temperature (20 to 25 degrees Celsius), does not require refrigeration, and ships as a standard pharmaceutical commodity in tamper-evident, child-resistant manufacturer packaging. Dispensing capability is therefore broader than for an infusion biologic, but the dispensing facility must hold a valid drug licence covering imported unregistered medicines and must operate an oncology pharmacy desk capable of family training on the on-an-empty-stomach administration requirement (no food for at least one hour before or two hours after each dose, because abiraterone exposure increases significantly with food and that exposure increase is associated with toxicity).
For patients identified at smaller oncology services without an in-house import pharmacy desk, the practical pattern is to route the case to a tertiary centre with an in-house import pharmacy, or to work through a CDSCO-licensed specialty importer in Mumbai, Delhi, or Bangalore that handles the Form 12A filing and the chain-of-custody documentation. Reserve Meds aligns with the importer on US-side sourcing and with the treating oncologist on clinical documentation. Multi-city and cross-border families are common, and Reserve Meds' single-coordinator model is built for that pattern.
Real cost picture for Akeega in India
Medicine price: quote on request. Every case gets a written custom quote before you commit.
The daily dose requires two tablets of that strength (or an equivalent combined-strength configuration) to deliver 200 mg niraparib plus 1,000 mg abiraterone acetate. Medicine price: quote on request. You get a written quote for your case before you commit. International payer pricing is highly variable. The Reserve Meds quote line for the medicine is sized to the supply duration agreed at intake.
International ambient-temperature shipping for Akeega is among the more forgiving logistics profiles for an oral oncology product. A 30-day course fits within a small parcel envelope, which simplifies customs declaration and last-mile delivery. Medicine price: quote on request. You get a written quote for your case before you commit. Tablets must remain in original sealed manufacturer packaging for chain-of-custody and import documentation, and heat-excursion risk during summer transit through northern Indian flight paths is a routing consideration the 3PL plans around. India's Union Budget 2026-27 fully exempted basic customs duty on a set of named cancer drugs and broadened the rare-disease list; the specific HSN code and exemption status of each Akeega shipment is confirmed at the documentation stage. GST on most life-saving medicines is 5 percent.
None of the major Indian private insurers reimburse a Rule 36 personal import of an unregistered oncology medicine as a standard line item. CGHS provides for life-saving and anti-cancer medicines that are not in the standard formulary to be considered case by case by an Expert Committee under Special DG (DGHS), with stricter constraints on drugs not approved by the DCGI; the family may pursue this evaluation but the operating expectation is cash-pay. Reserve Meds itemises the US-side procurement, the international logistics, and the coordination fee separately on every firm quote so that any reimbursement attempt the family chooses to pursue has clean documentation to work with.
Typical timeline for Akeega in India
CDSCO decides on the Form 12B permit after it reviews a complete Form 12A filing. We give you a written timeline estimate for your case before you commit. The ambient-temperature handling class keeps Akeega on standard international transit windows with no cold-chain time pressure.
Where BRCA testing is not yet complete at the time of inquiry, the BRCA result is the rate-limiting upstream step rather than the CDSCO permit. A germline test through a major tertiary cancer genetics service typically returns in two to four weeks; a comprehensive tumour genomic profile through FoundationOne CDx or equivalent typically returns in three to four weeks from sample receipt at the laboratory. Reserve Meds does not coordinate the BRCA testing step itself but flags the dependency at intake so the family understands the sequencing. Because Akeega is dosed daily on a continuous (not cycled) basis until disease progression or unacceptable toxicity, Reserve Meds plans repeat-shipment cadence at case acceptance, with the dose-modification triggers documented (niraparib reduction to 100 mg daily in two steps for hematologic toxicity, abiraterone held rather than reduced).
What your physician needs to provide
The clinical justification letter is the cornerstone of the Form 12A filing. For Akeega, the strongest letters consistently include: a treating oncologist's confirmed diagnosis of metastatic prostate cancer with castration status documented (mCRPC under the August 2023 FDA approval or BRCA2-mutated mCSPC under the December 2025 FDA expansion); the BRCA mutation result from FoundationOne CDx or equivalent comprehensive genomic profiling with the testing laboratory named; prior therapies tried and failed where applicable to the mCRPC indication; the proposed daily dose (200 mg niraparib plus 1,000 mg abiraterone acetate orally once daily on an empty stomach, with prednisone 10 mg once daily, and ongoing androgen deprivation therapy continued unless the patient has undergone bilateral orchiectomy); and the monitoring plan covering complete blood count weekly for the first month then monthly, blood pressure, liver function tests, serum potassium at baseline and at regular intervals, cortisol if adrenal insufficiency is suspected under stress, and long-term vigilance for myelodysplastic syndrome and acute myeloid leukemia. The prescribing oncologist's NMC registration number, the dispensing facility's drug licence, and a chain-of-custody plan from the US specialty pharmacy to the Indian dispensing pharmacy complete the file. Import documentation explicitly names BRCA-mutated metastatic prostate cancer as the indication so customs reviewers do not mischaracterize the shipment.
The treating oncologist retains the clinical decision and the Pharmacovigilance Programme of India (PvPI) adverse-event reporting obligation through the Indian Pharmacopoeia Commission for any imported product. Reserve Meds includes the PvPI reference in the physician documentation kit; the reporting obligation itself stays with the prescribing physician.
Common questions about Akeega in India
What if BRCA testing has not been done yet?
BRCA confirmation is mandatory before Akeega initiation under the FDA label. Reserve Meds flags the dependency at intake but does not coordinate the testing step itself. The first Akeega shipment is sequenced to follow the BRCA result.
What is the MDS and AML risk we should be aware of?
The FDA label warning on Akeega includes the PARP-class risk of myelodysplastic syndrome and acute myeloid leukemia, including fatal cases reported with niraparib and other PARP inhibitors. Long-term vigilance is required. The most common adverse reactions in the MAGNITUDE trial were anemia, hypertension, fatigue, constipation, nausea, and musculoskeletal pain. Abiraterone contributes hypertension, hypokalemia, fluid retention, and adrenocortical insufficiency under stress. The monitoring schedule is set by the treating oncologist.
Why the fixed-dose Akeega rather than separate niraparib (Zejula) and abiraterone (Zytiga)?
The fixed-dose tablet simplifies administration and adherence relative to two separately prescribed and separately sourced medicines, particularly while the patient is also managing prednisone and ongoing androgen deprivation therapy. The clinical decision belongs to the treating oncologist. Reserve Meds does not advise on the comparator choice.
What about the empty-stomach requirement?
The FDA label requires Akeega to be taken on an empty stomach, with no food for at least one hour before or two hours after each dose. This is because abiraterone exposure increases significantly when taken with food and that exposure increase is associated with toxicity. Family training at the dispensing pharmacy and follow-up reinforcement by the treating oncology team is the standard practice.
Will a private insurer cover Akeega?
Each plan handles named-patient imports case by case. None of the major Indian private insurers reimburse a Rule 36 personal import of an unregistered oncology medicine as a standard line item. Reserve Meds provides the itemised documentation that lets the insurer evaluate. Cash-pay is the working posture.
Does FCRA affect a diaspora-funded Akeega case?
The Foreign Contribution (Regulation) Act 2010 (FCRA), as proposed to be amended by the Foreign Contribution (Regulation) Amendment Bill 2026, regulates foreign donations to Indian organisations and individuals. For a patient family paying for the medicine themselves, including an adult child overseas paying for a parent's treatment, FCRA is generally not engaged. Where a foreign foundation or oncology-focused diaspora group is funding the treatment, FCRA registration of the recipient organisation and the donation route can become relevant. Reserve Meds does not provide FCRA legal advice; we flag the question so it reaches the right adviser early.
Where Reserve Meds fits in Akeega cases
Reserve Meds is a US-based digital health company. We do not replace your oncologist, do not replace CDSCO or the DCGI, and do not replace the dispensing hospital pharmacy or the licensed specialty importer, and we do not coordinate the BRCA testing step. What we do is orchestrate the supply through a US-licensed pharmaceutical wholesale partner from Janssen's limited-distribution network (including authorised partners such as Onco360) once the BRCA result is documented, ambient-temperature pharmaceutical logistics with documented temperature logging through a bonded pharmaceutical 3PL, and the documentation kit your treating oncologist needs for the Form 12A filing. Standard NPP coordination applies with particular attention to BRCA confirmation as the gating clinical criterion, the empty-stomach administration training at dispensing, the PARP-class monitoring cadence the oncologist holds, and clear indication labelling on customs documentation. A single point of contact carries the case from intake through continuous daily dosing until progression or unacceptable toxicity.
Next step
If an Indian patient with BRCA-mutated metastatic prostate cancer has an oncologist considering Akeega, start your case at the portal. We will respond within one business day with a documentation kit for your oncologist and a written quote.
Reserved for you.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Indian physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.